靶向基因检测组合用于识别运动障碍相关基因的评估
研究开发并评估了包含127个运动障碍相关基因的靶向测序组合,应用于2014年9月至2016年7月间法国、卢森堡和阿尔及利亚三级运动障碍中心收治的378例疑似遗传性运动障碍患者。结果显示22.0%的患者检出可能致病变异,其中帕金森综合征患者占55%。该靶向测序组合高效且成本效益优于全外显子组测序。
要点
- 靶向测序组合在378例疑似遗传性运动障碍患者中检出83例(22.0%)可能致病变异。
- 帕金森综合征患者占检出者的55%,而肌张力障碍患者诊断率较低(15.6%)。
- 该组合可作为全外显子组测序和全基因组测序的经济有效替代方案。
核心结论
- 高覆盖度测序组合用于运动障碍相关基因的筛查高效且经济,可作为全外显子组测序和全基因组测序的成本效益替代诊断方案。
研究设计与样本
- 研究选取127个运动障碍相关基因构建定制溶液捕获富集阵列,对2014年9月至2016年7月间来自1个卢森堡、1个阿尔及利亚和25个法国三级运动障碍中心的378例符合条件患者进行靶向高覆盖度测序。
- 患者因早发、家族史和/或复杂表型被怀疑患有遗传性运动障碍,分为帕金森综合征、肌张力障碍、舞蹈症、阵发性运动障碍和肌阵挛5个主要组。
- 另纳入23例疑似遗传性小脑共济失调患者进行全外显子组测序(WES)以比较方法。
- 数据分析时间为2015年11月至2016年10月。
主要发现
- 378例患者中208例(55.0%)为男性,发病年龄中位数(范围)为31(0-84)岁。
- 83例(22.0%)检出可能致病变异:帕金森综合征46例(占83例的55%)、肌张力障碍21例(25.3%)、舞蹈症7例(8.4%)、阵发性运动障碍7例(8.4%)、肌阵挛2例(2.4%)。
- 检出致病变异的患者年龄显著小于未诊断患者(中位年龄27岁,四分位距[IQR]5-36岁 vs 中位年龄35岁,IQR 15-46岁;P = .04)。
- 肌张力障碍患者诊断率显著低于整体队列(21/135;15.6%;P = .03)。
- 发现49个新可能致病变异,并观察到偏离经典表型的意外基因型-表型关联;23例小脑共济失调患者WES分析总体诊断率为26%,与组合分析相似但成本高6至7倍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Movement disorders are characterized by a marked genotypic and phenotypic heterogeneity, complicating diagnostic work in clinical practice and molecular diagnosis. OBJECTIVE: To develop and evaluate a targeted sequencing approach using a customized panel of genes involved in movement disorders. DESIGN, SETTING AND PARTICIPANTS: We selected 127 genes associated with movement disorders to create a customized enrichment in solution capture array. Targeted high-coverage sequencing was applied to DNA samples taken from 378 eligible patients at 1 Luxembourgian, 1 Algerian, and 25 French tertiary movement disorder centers between September 2014 and July 2016. Patients were suspected of having inherited movement disorders because of early onset, family history, and/or complex phenotypes. They were divided in 5 main movement disorder groups: parkinsonism, dystonia, chorea, paroxysmal movement disorder, and myoclonus. To compare approaches, 23 additional patients suspected of having inherited cerebellar ataxia were included, on whom whole-exome sequencing (WES) was done. Data analysis occurred from November 2015 to October 2016. MAIN OUTCOMES AND MEASURES: Percentages of individuals with positive diagnosis, variants of unknown significance, and negative cases; mutational frequencies and clinical phenotyping of genes associated with movement disorders. RESULTS: Of the 378 patients (of whom 208 were male [55.0%]), and with a median (range) age at disease onset of 31 (0-84) years, probable pathogenic variants were identified in 83 cases (22.0%): 46 patients with parkinsonism (55% of 83 patients), 21 patients (25.3%) with dystonia, 7 patients (8.4%) with chorea, 7 patients (8.4%) with paroxysmal movement disorders, and 2 patients (2.4%) with myoclonus as the predominant phenotype. Some genes were mutated in several cases in the cohort. Patients with pathogenic variants were significantly younger (median age, 27 years; interquartile range [IQR], 5-36 years]) than the patients without diagnosis (median age, 35 years; IQR, 15-46 years; P = .04). Diagnostic yield was significantly lower in patients with dystonia (21 of 135; 15.6%; P = .03) than in the overall cohort. Unexpected genotype-phenotype correlations in patients with pathogenic variants deviating from the classic phenotype were highlighted, and 49 novel probable pathogenic variants were identified. The WES analysis of the cohort of 23 patients with cerebellar ataxia led to an overall diagnostic yield of 26%, similar to panel analysis but at a cost 6 to 7 times greater. CONCLUSIONS AND RELEVANCE: High-coverage sequencing panel for the delineation of genes associated with movement disorders was efficient and provided a cost-effective diagnostic alternative to whole-exome and whole-genome sequencing.
引用
- Montaut S, Tranchant C, Drouot N, et al. Assessment of a Targeted Gene Panel for Identification of Genes Associated With Movement Disorders. JAMA Neurol. 2018. PMID: 29913018. doi:10.1001/jamaneurol.2018.1478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。